{"id":105387,"date":"2025-10-27T08:11:56","date_gmt":"2025-10-27T13:11:56","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/nytt-hap-innen-malrettet-behandling-av-histiocytose\/"},"modified":"2025-10-27T08:40:45","modified_gmt":"2025-10-27T13:40:45","slug":"nytt-hap-innen-malrettet-behandling-av-histiocytose","status":"publish","type":"post","link":"https:\/\/www.erdheim-chester.org\/no\/nytt-hap-innen-malrettet-behandling-av-histiocytose\/","title":{"rendered":"Nytt h\u00e5p innen m\u00e5lrettet behandling av histiocytose"},"content":{"rendered":"<div>\n<p class=\"x_MsoNormal\"><span data-olk-copy-source=\"MessageBody\">En ny studie fra <b>Memorial Sloan Kettering Cancer Center<\/b> viser at <b>ulixertinib<\/b>, et m\u00e5lrettet legemiddel som blokkerer ERK, er lovende for behandling av visse former for <b>histiocytose<\/b>, inkludert <b>Erdheim-Chesters sykdom (ECD).<\/b><\/span><\/p>\n<p class=\"x_MsoNormal\">Denne forskningen, som ledes av Dr. Eli Diamond, medlem av ECDGAs Medical Advisory Board, markerer et spennende skritt fremover i behandlingen av MAPK-drevne histiocyt\u00e6re lidelser. For mange i samfunnet v\u00e5rt, som Joey, et medlem av ECDGA hvis reise fortsetter \u00e5 inspirere oss, representerer disse vitenskapelige gjennombruddene langt mer enn kliniske fremskritt. De gir h\u00e5p.  <\/p>\n<p class=\"x_MsoNormal\">Les nyhetsartikkelen fra MSKCC:<br \/>\n<a title=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" href=\"https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"2\">https:\/\/www.mskcc.org\/news\/targeted-therapy-drug-ulixertinib-for-histiocytosis-blood<\/a><\/p>\n<p class=\"x_MsoNormal\">F\u00e5 tilgang til hele den tekniske artikkelen i <i>Cancer Cell<\/i>:<br \/>\n<a title=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064\" target=\"_blank\" rel=\"noopener\" data-auth=\"NotApplicable\" data-linkindex=\"3\">https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1535610825004064<\/a><\/p>\n<p class=\"x_MsoNormal\">I ECDGA er vi stolte av \u00e5 st\u00f8tte og dele forskning som f\u00f8rer oss n\u00e6rmere bedre behandling, flere svar og, en dag, en kur.<\/p>\n<p><em>Den Erdheim-Chester Disease Global Alliance (ECDGA) gir ikke medisinske r\u00e5d, diagnoser eller behandlinger. Alt innhold er kun ment som informasjon. Vennligst r\u00e5df\u00f8r deg med helsepersonell ved medisinske bekymringer.  <\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>En ny studie fra Memorial Sloan Kettering Cancer Center viser at ulixertinib, et m\u00e5lrettet legemiddel som blokkerer ERK, er lovende for behandling av visse former for histiocytose &#8211; inkludert Erdheim-Chesters sykdom (ECD).<\/p>\n","protected":false},"author":14,"featured_media":105375,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_wds_title":"","_wds_metadesc":"","_wds_focus-keywords":"","_wds_meta-robots-adv":"","_wds_meta-robots-noindex":false,"_wds_meta-robots-nofollow":false,"_wds_meta-robots-index":false,"_wds_meta-robots-follow":false,"_wds_autolinks-exclude":false,"_wds_canonical":"","_wds_redirect":"","_wds_opengraph":[],"_wds_twitter":[],"cybocfi_hide_featured_image":"","wds_primary_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[418],"tags":[443,2644,5149,5145,5159,5157,1162,5144,5151,5153,5155,4353,5147,3538,5042],"class_list":["post-105387","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ecdga-nyheter","tag-ecd-bevissthet","tag-elidiamond-no","tag-erdheim-chestersykdom","tag-erkinhibitor","tag-forskningsgjennombrudd-2","tag-histiocytaere-sykdommer","tag-histiocytose","tag-malrettet-behandling-2","tag-mapkpathway","tag-memorialsloankettering","tag-presisjonsmedisin-2","tag-rarediseaseresearch-no","tag-sjelden-kreft-2","tag-sjeldenblodkreft","tag-ulixertinib"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/posts\/105387","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/comments?post=105387"}],"version-history":[{"count":0,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/posts\/105387\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/media\/105375"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/media?parent=105387"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/categories?post=105387"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/no\/wp-json\/wp\/v2\/tags?post=105387"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}